SOX方案和GP方案治疗晚期三阴性乳腺癌效果和安全性对比

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo evaluate the difference in the efficacy and adverse reactions of application of Oxaliplatin plus S-1 and Gemcitabine plus Cisplatin in treatment of advanced triple negative breast cancer.MethodsAltogether 76 cases of untreated triple negative breast cancer patients with Eastern Cooperative Oncology Group(ECOG)score≤1 were treated from January 2012 to January 2015 in our hospital were randomly divided into SOX Group(38 cases)and GP Group(38 cases).Two groups were treated with Oxaliplatin plus S-1 and Gemcitabine plus Cisplatin respectively for at least 8 cycles(21 days as a cycle)so as to compare the clinical response rate(RR),overall survival(OS),progression free survival(PFS)and adverse reactionsabove GradeⅢof two groups.ResultsThe median follow-up time of the two groups was 22.4(18.2-25.7)months and 23.3(17.8-24.9)months respectively,the total RR and disease control rate(DCR)of SOX Group were 57.89%(22/38)and 76.32%(29/38)respectively in contrast with GP Group′s 63.16%(24/38)and 73.68% (28/38);no significant difference was seen between OS of two groups[HR=0.93,95%CI(0.65,1.36),P＜0.05];the PFS of GP Group was significantly higher than that of SOX Group[HR=0.71,95%CI(0.53,0.92),P＞0.05].No statistically significant difference was found in the incidence of adverse reactions above GradeⅢbetween the two groups(P＞0.05).ConclusionAlthough Gemcitabine plus Cisplatin shows priority over Oxaliplatin plus S-1 in progression free survival time，no significant difference has been seen in the total survival time and incidence of adverse reactions above GradeⅢ between two regimens.Both of the two regimens are safe and effective in treatment of advanced triple negative breast cancer.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SU Wei-min
	YANG Ding-hon
	LIN Chang-yu

Cite this article:

SU Wei-min,YANG Ding-hon,LIN Chang-yu. Comparison of efficacy and safety of SOX regimen and GP regimen in the treatment of advanced triple negative breast cancer[J]. 中国当代医药, 2017, 24(17): 69-71.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I17/69

[1]	倪晨，李婷，吴振华，等.三阴性乳腺癌化疗进展[J].中国癌症杂志，2014，（4）：316-320.
[2]	徐兵河，江泽飞，胡夕春.中国晚期乳腺癌临床诊疗专家共识2016[J].中华医学杂志，2016，96（22）：1719-1727.
[3]	李春艳，王培，张晟，等.三阴性乳腺癌的临床病理特征和预后分析[J].中华肿瘤杂志，2013，35（6）：463-467.
[4]	余峰，张霄蓓，张晟，等.三阴性乳腺癌复发特征及危险因素分析[J].中华医学杂志，2014，94（28）：2180-2183.
[5]	皋文君，刘砚燕，袁长蓉.国际肿瘤化疗药物不良反应评价系统—通用不良反应术语标准4.0版[J].肿瘤，2012，32（2）：142-144.
[6]	刘俊彦，王哲海，郭珺，等.晚期三阴性乳腺癌的临床病理特征及预后分析[J].实用医学杂志，2013，29（3）：429-431. [7]陈洪流.三阴性乳腺癌患者的临床特征及预后因素[J].中国老年学杂志，2013，33（23）：5840-5841.
[8]	中国女医师协会临床肿瘤学专业委员会中国抗癌协会乳腺癌专业委员会.中国进展期乳腺癌共识指南（CABC 2015）[J].癌症进展，2015，13（3）：223-245.
[9]	王碧芸，龚成成，胡夕春.2015版《中国抗癌协会乳腺癌诊治指南与规范》：药物治疗策略的解读[J].中华乳腺病杂志（电子版），2016，10（2）：65-70.
[10]	尼杰，智英辉，只向成.P53在三阴性乳腺癌中的表达及其与铂类化疗药物敏感性的关系[J].天津医药，2013，41（4）：317-320.
[11]	师丙帅，王文胜，赵爱国，等.奈达铂联合吉西他滨治疗转移性三阴性乳腺癌近期疗效观察[J].实用医学杂志，2014，30（13）：2154-2156.
[12]	Hu XC，Zhang J，Xu BH，et al.Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatictriple-negativebreastcancer（CBCSG006）:arandomised，open-label，multicentre，phase3trial[J].LancetOncol，2015，16（4）：436-446.
[13]	叶万立，王建芳，杨红建.多西紫杉醇联合替吉奥对蒽环类耐药TNBC患者的临床疗效观察[J].中国生化药物杂志，2014，34（3）：116-118.
[14]	朱德淼，李锦成.TP新辅助方案治疗三阴性乳腺癌疗效的临床研究[J].医学与哲学，2015，36（4B）：31-33，63.
[15]	Liu J，Xiao Y，Wei W，et al Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer[J].Exp Ther Med，2015，10（1）：379-385.